Form 4: STAAR Surgical Grants RSUs to Interim Co-CEO Andrews

STAAR Surgical Co. granted 20,787 restricted stock units to Deborah J. Andrews, Interim Co-CEO and CFO, in connection with her appointment.

Summary

• Deborah J. Andrews, Interim Co-CEO and CFO of STAAR Surgical Co., was granted 20,787 Restricted Stock Units (RSUs).
• The grant was made on February 2, 2026, in connection with her appointment as Interim Co-Chief Executive Officer.
• Each RSU represents the right to receive one share of the Corporation's common stock upon vesting.
• These RSUs will vest as to 100% of the shares on August 1, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents a standard executive compensation practice that aligns management incentives with shareholder interests, without indicating any significant operational or financial changes.

Positives

• The RSU grant aligns the interests of Interim Co-CEO and CFO Deborah J. Andrews with those of shareholders, as her compensation is tied to the company's stock performance.
• The grant is a standard component of executive compensation, reflecting a commitment to retaining and incentivizing key leadership.

Future Outlook

The granted Restricted Stock Units are scheduled to vest on August 1, 2026, which will result in Deborah J. Andrews receiving 20,787 shares of STAAR Surgical Co. common stock.

Management Comments

• The award of RSUs was granted to Deborah J. Andrews in connection with her appointment as Interim Co-Chief Executive Officer on February 2, 2026.

Industry Context

StockSavvy.ai notes that RSU grants are a common and widely accepted form of executive compensation across various industries, including medical devices, serving to incentivize long-term performance and align management interests with shareholder value creation.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) to an executive upon appointment to a new leadership role, such as Interim Co-CEO, is a standard practice in publicly traded companies across industries, including medical technology firms like STAAR Surgical Co.
• Companies such as Medtronic (MDT) and Abbott Laboratories (ABT) frequently utilize RSU grants as part of their executive compensation packages to attract, retain, and motivate top talent, linking executive wealth directly to the company's stock performance over time.

Management Changes

Stakeholder Impact

• Shareholders: The RSU grant aligns executive incentives with shareholder value, potentially leading to better long-term performance, though it also represents a minor potential for future share dilution upon vesting.
• Employees: The compensation package for a key executive can influence overall employee morale and perception of company leadership's commitment.

Next Steps

• The 20,787 Restricted Stock Units granted to Deborah J. Andrews are scheduled to vest on August 1, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine RSU grant to an executive following an appointment, which is a standard compensation practice. It does not contain information that would significantly alter the fundamental investment thesis for STAAR Surgical Co., thus a 'hold' recommendation is appropriate as it provides no new strong buy or sell signals.

Keywords

STAAR Surgical, STAA, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Form 4, Deborah J. Andrews, Interim Co-CEO, CFO